[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 17,721
Citations 0
JAMA Patient Page
June 18, 2020

What Is Anosmia?

Author Affiliations
  • 1Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 2Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins Hospital, Baltimore, Maryland
JAMA. Published online June 18, 2020. doi:10.1001/jama.2020.10966

Anosmia (the inability to smell) and hyposmia (a decreased ability to smell) describe the range of olfactory dysfunction, or smell disorders.

The ability to smell is a complex process involving the nose and brain. When air passes into the nose, odor molecules bind to the receptors of olfactory nerves. These nerves are found in a specialized lining at the top of the nasal cavity called the olfactory epithelium. The stimulation of olfactory nerves causes them to transmit a signal to the brain, where it is processed into a scent that a person can recognize and identify.

Causes of Olfactory Dysfunction

Smell disorders such as anosmia affect about 15 of every 1000 people in the United States and are more common with older age. Some common causes include sinonasal disorders such as allergic rhinitis (hay fever) and nasal polyps, head trauma, and infections such as viral illnesses. Anosmia can also be congenital (present at birth), idiopathic (no known cause), or related to dementia such as Parkinson disease or Alzheimer disease.

There have also been reports of acute-onset (sudden) anosmia, sometimes in the absence of other symptoms, as a marker of coronavirus disease 2019 (COVID-19), an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Diagnosis

Smell disorders can occur suddenly, such as after a viral illness or trauma, or gradually. Diagnosis usually starts with patient self-reporting, although not all patients who have measurable olfactory dysfunction realize it.

To determine the cause, a clinician may ask about recent illnesses or head or facial injury, when the decreased ability to smell was first noticed, and if there are any other symptoms. The examination may also include nasal endoscopy to look for obstructive causes such as polyps or swelling, or imaging such as computed tomography or magnetic resonance imaging. The patient may also be asked to take tests to identify common odors to determine the severity of olfactory dysfunction. Given that acute-onset olfactory dysfunction is included in the diagnostic criteria for COVID-19, the patient may undergo SARS-CoV-2 testing, and clinicians may wear personal protective equipment (PPE) during the examination.

Treatment and Management

Treatment of olfactory dysfunction depends on the cause. Up to two-thirds of cases associated with viral illness resolve on their own. During the COVID-19 pandemic, patients may be asked to self-isolate for about 2 weeks or until being tested for SARS-CoV-2 to protect others. Cases related to nasal obstruction (polyps, allergic rhinitis) require treatment of those underlying causes. Olfactory training, which involves daily exposure to a set of common odors, is another treatment option. Further research is being done on the ability of damaged olfactory neurons (nerve cells) to regenerate and the role of medications to support this.

The ability to smell also contributes to one’s quality of life. If you feel your quality of life has been reduced because of a decreased ability to smell, talk to a health care practitioner. For safety, people who have lost their sense of smell should maintain fire and natural gas alarms and avoid eating foods past their expiration dates.

Box Section Ref ID

For More Information

The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, email reprints@jamanetwork.com.
Back to top
Article Information

Published Online: June 18, 2020. doi:10.1001/jama.2020.10966

Conflict of Interest Disclosures: None reported.

Sources: Whitcroft KL, Hummel T. Clinical diagnosis and current management strategies for olfactory dysfunction: a review. JAMA Otolaryngol Head Neck Surg. 2019;145(9):846-853.

Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. Published online May 20, 2020. doi:10.1001/jama.2020.8391

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×